Articles tagged with B Lymphocytes
Researchers have identified a new approach to treating chronic graft-versus-host disease, targeting T and B cells with the FDA-approved drug ibrutinib. The study found that ibrutinib reduced chronic GVHD in mice models and decreased activation of T and B cells isolated from patients with chronic GVHD.
Researchers have established a crucial relationship between Natural Killer T (NKT) cells and B cells in the body's natural defense mechanisms. The study found that altered lipid compositions on autoimmune B cells lead to over-activation of NKT cells, causing their depletion. Removing a specific lipid-presenting molecule from B cells re...
Scientists at the Max Planck Institute re-activated an ancient gene, FOXN4, which led to the development of a fish-like thymus in mice. This finding suggests that the immune system's core organs may have evolved from a common ancestor with jawed fish.
Researchers discovered that innate lymphoid cells become activated during inflammation, inducing specific T and B cell responses. These findings open up new avenues for treating infection and chronic inflammation.
A new study published in the Journal of Leukocyte Biology suggests that modulation of B cells may effectively treat and/or prevent periodontitis symptoms related to type 2 diabetes. Researchers used a mouse model to demonstrate the B cell-response's viability as a target for pharmacological intervention.
A biomedical engineer has received a $250,000 grant to expand his research on a novel lupus drug that targets B cells. The goal is to treat a range of autoimmune diseases, offering an alternative to steroids with fewer side effects.
Researchers at the Garvan Institute of Medical Research have discovered that B cells participate in the development of regulatory T cells, which control how killer T cells behave. This finding has implications for treating autoimmunity and preventing transplant rejection.
Researchers at The Wistar Institute discovered that the protein Foxp1 plays a critical role in antibody responses, enabling rapid and effective immune system activation. Manipulating Foxp1 activity could provide a useful tool for boosting antibody responses to treat infectious diseases or suppressing them to treat autoimmune disorders.
Researchers at Beth Israel Deaconess Medical Center have identified a new B-cell selection process that influences antibody survival independent of antigen-binding regions. This discovery adds a surprising dimension to the understanding of antibody repertoires and may help shape them to better fight disease.
Researchers at UCLA discovered that B cells respond to threats by producing antibodies only when a high threshold is reached, reducing the risk of false alarms. This mechanism helps prevent immune deficiency and autoimmune diseases.
A new study found that reducing B cell levels can significantly decrease brain lesions and disease activity in people with relapsing-remitting MS. The research showed that maintaining B cell levels below a threshold of 32-64 cells per microliter resulted in an annualized rate of less than one new brain lesion per year.
Scientists have created a detailed map of human B cell development at the single-cell level, improving research capabilities and identifying rare aberrations that lead to disease. The approach will guide regenerative medicine and help understand complex developmental processes.
A team of Dana-Farber Cancer Institute investigators have uncovered a connection between Down syndrome and the development of acute lymphoblastic leukemia (ALL) during childhood. The study found that an extra copy of chromosome 21 leads to abnormal B cells that grow uncontrollably, increasing the risk of ALL.
Researchers discovered that enhancers play a crucial role in controlling somatic hypermutation by marking specific sites for hypermutation on antibody genes. This breakthrough resolves a long-standing scientific debate and provides new insights into the targeting mechanism of hypermutation.
Scientists have discovered that B-lymphocytes lack the protein PTP1B, making them hyperactive and promoting an autoimmune attack. This study provides a new mechanism for how B-cells regulate an immune response, potentially playing a significant role in autoimmune diseases such as rheumatoid arthritis.
Researchers have sequenced the functional part of the genome of leukaemia cells and identified thousands of genes expressed differently in leukaemia cells compared to healthy B lymphocytes. The study revealed two subgroups of patients with distinct disease behaviors, one requiring minimal treatment and the other needing prompt treatment.
Researchers have discovered a novel immunological mechanism that regulates B lymphocytes to fight encapsulated bacteria, clearing the path for more efficient vaccines. This discovery improves our understanding of the immune system's protection against infections.
Aortic valve replacement improves symptoms but may not improve overall quality of life for high-risk patients. Researchers found rituximab to be ineffective in treating primary Sjögren's syndrome, while microsporidiosis should be considered in febrile transplant patients, especially those with unexplained illnesses.
In this study, researchers identified a unique regulatory T cell population in human skin that plays a crucial role in dampening the immune response against self-antigens. However, in inflamed skin, such as in psoriasis, this population is dysfunctional and fails to suppress autoimmunity.
Researchers discovered a genetic variant that influences vaccine response and autoimmune disease risk. Individuals with this variant express an additional immune system receptor on their B cells, which activates antibody production, potentially leading to autoimmune diseases.
A personalized cell therapy reprograms a patient's immune system to eliminate tumors in blood, showing complete responses in 89% of patients with high-risk ALL. The treatment has also been shown to persist in circulation and prevent cancer recurrence.
Researchers found that a specific molecular process controls B cell activation and differentiation, leading to impaired antibody production. The study highlights the importance of genes like IL-21 receptor, STAT3, and CD25 in B cell function, with mutations causing debilitating effects in patients.
B cells circulating through the liver are first depleted after treatment with anti-CD20 antibodies. The study reveals a vital role of liver Kupffer cells in deleting B cells and provides techniques to improve the effectiveness of anti-CD20 therapy.
Researchers found that liver Kupffer cells are essential for deleting B cells using anti-CD20 therapy. The interaction between the liver and the immune system also affects the progression of candidiasis, a leading cause of hospital-acquired infections.
Researchers found that re-activating normal aging in tumor cells can inhibit proliferation, offering a potential new therapeutic target for treating diffuse large B-cell lymphoma. The study identified Smurf2 as a key player in this process and suggests that increasing its expression may lead to improved treatment outcomes.
Researchers discovered how EBV infection evades detection by the immune system, triggering molecular events that turn off key proteins. This finding could lead to a vaccine that provides immunity from ever being infected with EBV.
Researchers found that CVID patients with a single altered TACI allele maintain some residual B cell responsiveness, promoting autoantibody development. In contrast, individuals with two mutated copies of TACI have complete impairment of B cell responses, likely preventing autoimmunity.
Monash University researchers discovered a safety mechanism that regulates the activation of marginal zone B cells, which can turn against the body. The study found that MZ B cells have a short life span and are triggered by bacteria to express a protein called TACI.
Researchers have identified a type of white blood cell in lampreys that resembles gamma delta T cells found in mammals and birds. The discovery suggests that distinct cells with similar functions may have existed in the last common vertebrate ancestor, providing insights into the evolutionary past.
A Scripps Research Institute study found that overproduction of a specific cluster of microRNAs can trigger lymphomas. The research identified key biological pathways involved in cancer growth and offers new potential therapy targets.
Researchers tracked the movement of specialized cells to shed light on the immune system's response to invading pathogens. The study found that T follicular helper cells continually move between germinal centers within lymph nodes, potentially enhancing antibody production.
Researchers have discovered how an experimental drug can completely eradicate human lymphoma in mice after just five doses by gumming up the powerful master regulatory transcription factor Bcl6. The study provides a promising new strategy to treat diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma.
Researchers discovered that the transcription factor EBF1 is crucial for maintaining B cell identity and preventing alternative fates. When EBF1 was switched off, transplanted B cells forgot their previous identity and developed into T cells and natural killer cells.
Scientists at Northwestern University have successfully transplanted rat islets into mice, producing insulin for over 300 days without immunosuppressive drugs. This breakthrough method uses a unique approach to control rejection and has significant implications for future interspecies transplants.
A team of scientists at Scripps Research Institute identified a family of tiny RNA molecules that work as powerful regulators of the immune response in mammals. These RNA molecules enable the differentiation of T cells into follicular helper T cells, which assist B cells in producing antibodies.
Researchers discovered that inhibiting powerful protein EZH2 with new agents may supply broad benefit for lymphoma patients. The study found that EZH2 is a key driver of cancer in B-cells, and its inhibition can help treat follicular lymphoma and diffuse large B-cell lymphomas.
Researchers used high-quality video imaging to investigate why a particular cancer drug is effective at killing cells. The study found that the drug creates a cluster of protein molecules on one side of the cell, making it easier for natural killer cells to kill it.
New research reveals that fish oil can enhance the function of white blood cells called B cells, contradicting previous assumptions of its only immunosuppressive properties. This discovery may lead to the use of fish oil among those with compromised immune systems.
A team of scientists developed a new technique for designing vaccine immunogens that can stimulate the immune system to produce antibodies effective against multiple strains of HIV. The approach, using artificial proteins engineered to bind germline B cells, offers hope for better protection against fast-mutating viruses.
A novel T-cell therapy has demonstrated complete remission in two pediatric patients with acute lymphoblastic leukemia (ALL), a high-risk type of cancer. The treatment, which reprograms the immune cells to target specific cancer cells, has shown promising results but also carries potential side effects.
Researchers at Children's Hospital of Philadelphia report complete remission in two pediatric ALL patients treated with novel cell therapy. The treatment, known as CTL019, uses engineered T cells that target a specific protein on the surface of leukemia cells, achieving a potent anticancer effect.
Researchers have discovered that a protein switch called Ebf2 determines the development of brown fat cells, which are thought to counteract obesity by burning excess energy. The study found that Ebf2 regulates the binding activity of PPAR-gamma, a protein that regulates differentiation of developing cell types.
A study from Boston University School of Medicine reveals that B cells secrete pro-inflammatory cytokines promoting insulin resistance and directly regulating inflammatory T cells. This discovery supports the exploration of FDA-approved B cell depletion drugs as novel agents to prevent obesity-associated inflammation and type 2 diabetes.
Researchers found that B cells improve antibody molecules through a process of somatic hypermutation, increasing selection pressure on their own products. This mechanism could accelerate vaccination methods by producing optimal antibodies earlier.
Researchers at Weill Cornell Medicine have made a breakthrough in treating diffuse large B-cell lymphoma by targeting the master regulatory transcription factor Bcl6. By shutting down this protein, patients may experience fewer side effects and improved treatment outcomes.
Researchers at UT Southwestern Medical Center have discovered an osteoblastic niche in the bone marrow that nurtures early lymphoid progenitors, specialized blood-forming cells responsible for producing T cells and B cells. This finding may lead to improved safety and effectiveness of bone-marrow transplants and treatments for illnesse...
Researchers from Beth Israel Deaconess Medical Center have discovered a second B-cell attachment receptor for the Epstein-Barr virus, which could lead to the development of a vaccine. The new finding also raises questions about the virus's possible relationship to malaria and autoimmune diseases.
Researchers discovered a specific B lymphocyte marker that indicates the onset of cGVHD, a devastating syndrome where the patient's tissues are attacked by transplanted immune cells. This easily measured marker could help guide new therapies to mitigate or prevent cGVHD, which affects half of all bone marrow transplant procedures.
Researchers discovered a novel class of early replicating fragile sites contributing to genome instability in B cell lymphomas. These sites, uncovered through genome-wide sequencing, overlap with mutations associated with the disease and suggest a major feature of its mutational landscape.
Researchers at Helmholtz Centre for Infection Research discovered that antibodies are essential for dendritic cell maturation, a process critical to the immune response against pathogens. The study highlights the complex interplay between innate and acquired immunity, showing how antibodies facilitate communication between immune cells.
Researchers at Northwestern University discovered a new nanoparticle that kills B-cell lymphoma cells by depriving them of natural HDL cholesterol. The nanoparticle, which mimics the size and shape of HDL particles, blocks cholesterol from entering cancer cells, leading to cell death.
Researchers at UCSF discover an 'immune exchange' between the brain and blood that allows disease-causing B cells to move in and out of the brain, providing a potential key to unlocking better treatments and diagnostics. The study suggests that targeting specific B cells could lead to precision therapies tailored to each patient's needs.
Scientists confirm that an infection can trigger an autoimmune disease by identifying the exact conditions for an autoantibody response to occur. The research reveals a unique problem with the immune system's ability to distinguish between self and non-self, leading to autoimmunity in certain cases.
Researchers found that targeting CD22 protein on lung cancer cells reduces tumor growth and metastasis in mouse models, leading to improved survival rates. The discovery may lead to the development of a novel therapy for non-small cell lung cancer.
Researchers at Duke University Medical Center have discovered a rare type of B cell that regulates immune responses and limits autoimmunity. By infusing these cells into mice with autoimmune disease, symptoms were significantly reduced. Further research is needed to expand human B10 cells and determine their behavior in humans.
Researchers at MDC Berlin-Buch identified subpopulations of B cells with activated Myc genes, essential for germinal center formation and maintenance. These findings shed light on the origin of B-cell lymphomas derived from germinal centers.
Researchers have identified how immature immune cells respond to the influenza virus and traced the path to generate antibodies that can neutralize a wide range of strains. This understanding could aid in designing a universal flu vaccine that provides protection against most or all influenza virus strains.
Researchers found that B cells from patients with chronic GVHD are more active and resistant to programmed cell death. The study identifies BAFF as a promising target for developing new therapies, such as anti-BAFF agents or small molecule inhibitors.
Researchers at MDC Berlin-Buch have identified a critical enzyme, PI3K, that enables c-MYC to transform B lymphocytes into malignant cells. This finding may lead to effective treatments by inhibiting the PI3K signaling pathway.
A study published in Journal of Neuroimmunology suggests that B cells, a type of immune cell, produce toxic substances that damage myelin and contribute to the progression of multiple sclerosis. Researchers hope to identify these substances to develop targeted therapies for MS treatment.